Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Harold E. Glass"'
Publikováno v:
Pharmaceutical Medicine. 30:109-115
Some industry observers and medical professionals, and even the popular media, assert that pharmaceutical companies are conducting an increasing number of clinical trials in countries outside the more established geographies of North America and West
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fe34cf4c2fe888213b9c7ee4eccd5a4
https://doi.org/10.1007/s40290-015-0135-1
https://doi.org/10.1007/s40290-015-0135-1
Publikováno v:
Therapeutic innovationregulatory science. 50(6)
The pharmaceutical industry has continued to experience a large number of mergers, often involving the very largest companies. Behind many of these mergers has been the desire to achieve scale efficiencies and improved performance in both commercial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0f5b7c595daba73e9bdfabc2d819d62
https://pubmed.ncbi.nlm.nih.gov/30231738
https://pubmed.ncbi.nlm.nih.gov/30231738
Publikováno v:
Therapeutic innovationregulatory science. 49(6)
This study uses the data from many of the mandatory fields in ClinicalTrials.gov to examine changes, possibly leading to more complexity in the design and execution of commercially sponsored phase 3 clinical trials.In this analysis we compare baselin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55df582b0ce430894e290715d6109ecd
https://pubmed.ncbi.nlm.nih.gov/30222375
https://pubmed.ncbi.nlm.nih.gov/30222375
Autor:
Harold E. Glass
Publikováno v:
Therapeutic innovationregulatory science. 54(2)
The Open Payments database represents a new, substantial source of information on the US clinical trial investigator landscape.This paper draws upon the Open Payments database. This database, mandated by the US Sunshine Act, does help provide a vital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d8852b0856631dbc7f8f83f6c0559b7
https://pubmed.ncbi.nlm.nih.gov/32072576
https://pubmed.ncbi.nlm.nih.gov/32072576
Publikováno v:
Therapeutic Innovation & Regulatory Science. 49:218-224
Since 2007, the US federal government has required that organizations sponsoring clinical trials with a least one site in the United States submit information on these clinical trials to an existing database: ClinicalTrials.gov . Over time, the numbe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8bd6924556bbdabd6b66d87ca2e28a
https://doi.org/10.1177/2168479014551643
https://doi.org/10.1177/2168479014551643
Autor:
Harold E. Glass, Jesse M. Glass
Publikováno v:
Pharmaceutical Medicine. 25:87-94
Introduction: Latin America currently represents a relatively small but constant number of clinical sites for commercially funded studies. This article describes the profiles of sites and investigators involved in commercial clinical research and com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50668b52da5e85cf19e80df9f6ff19c4
https://doi.org/10.1007/bf03256850
https://doi.org/10.1007/bf03256850
Autor:
Karen Hollander, Harold E. Glass
Publikováno v:
Contemporary Clinical Trials. 30:221-226
The rapidly increasing cost of pharmaceutical R&D presents a major challenge for the industry. This paper examines one aspect of that spending, clinical grants, and presents ways that pharmaceutical companies can best manage those expenditures. The f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a95bbdf89dd5671553f19f5da1bf2cc5
https://doi.org/10.1016/j.cct.2009.02.001
https://doi.org/10.1016/j.cct.2009.02.001
Autor:
Laurence G. Poli, Harold E. Glass
Publikováno v:
International Journal of Pharmaceutical and Healthcare Marketing. 3:74-83
PurposeThe pharmaceutical industry faces significant challenges in the immediate future, including drug safety, intellectual property in emerging markets, industry image, and the overall effect of marketing. To remain effective, pharmaceutical execut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6dc5be0f9301c87ba45b992f9146052d
https://doi.org/10.1108/17506120910948520
https://doi.org/10.1108/17506120910948520
Autor:
Harold E. Glass
Publikováno v:
Pharmaceutical Medicine. 23:85-90
Background: Studies managed by contract research organizations (CROs) make up a significant portion of all clinical research activities. Despite this, there have been few analyses of investigator attitudes about the type of organization (i.e. CRO or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d37d741c41a612a03a79bdd8e02e025
https://doi.org/10.1007/bf03256754
https://doi.org/10.1007/bf03256754
Autor:
Harold E. Glass
Publikováno v:
Contemporary Clinical Trials. 30:34-39
The FDA database on investigators completing the 1572 form constitutes a rich database of practicing investigators. Within the most recent three-year period, roughly half of all the principal investigators appear only once in the 1572 database, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d5c2198a86b4ac09b18a63187cb05ba
https://doi.org/10.1016/j.cct.2008.09.008
https://doi.org/10.1016/j.cct.2008.09.008